Pharmaceutical-grade research supply
Retatrutide
30 mg • GLP-1 / GIP / GCGR
Triple GLP-1 / GIP / GCGR agonist.
Triple agonist of the GLP-1, GIP, and glucagon receptors synthesized to research-grade purity — 30 mg per vial, HPLC-verified and mass-spec confirmed. For laboratory research use only.
Shopify button not yet configured for this product.
Admin: paste the Shopify Buy Button embed code in the product editor.
Key research benefits
- Triple agonism: GLP-1, GIP, glucagon
- 30 mg lyophilized per vial
- HPLC-verified purity ≥99.5%
- Third-party mass-spec identity confirmation
- Full chain-of-custody documentation
Specifications
Details
Retatrutide (research code LY3437943) is a novel triple-agonist peptide targeting the GLP-1, GIP, and glucagon (GCGR) receptors simultaneously. It has attracted significant interest in metabolic and endocrine research programs.
Each vial contains 30 mg of lyophilized retatrutide sealed under inert atmosphere. Every lot is HPLC-purity tested and mass-spec identity confirmed by an independent third-party laboratory, with a lot-specific Certificate of Analysis available on request.
For research and licensed clinical use only. Not for human consumption unless prescribed by a licensed medical professional.
Frequently asked questions
Related research supplies
For research use only. Not for human consumption or therapeutic use. All products are intended solely for in-vitro laboratory research and are not to be used for diagnostic or therapeutic purposes.